Saxagliptin Hydrate

沙格列汀水合物

Report date: 2022/05/18 16:15:19
NME

Base Information

Drug NameSaxagliptin Hydrate
Drug Alias NameSaxagliptina沙格列汀单水化合物Saxagliptine沙格列汀盐酸盐沙萨格列汀 +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDipeptidyl peptidase IV inhibitors
TargetsDipeptidyl peptidase IV
Therapy Area/IndicationsHypoglycemiaDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1 +[4] 
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryUnited States
Original Approved Date2009/07/31
Country/TerritoryCzechiaBelgiumBulgaria +[44] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesKyowa Hakko Kirin Co LtdAstrazeneca AbBristol-Myers Squibb Company +[4] 
Inactive CompaniesKyowa Kirin Co LtdBristol Myers Squibb SrlcompanyAstrazeneca Pharmaceutical Co Ltd +[6] 
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsHypoglycemiaDiabetes Mellitus, Type 1Diabetes Mellitus

Other Information

ATC CodeA10BH03
Related LinksWikipediaDrugBankKEGG